Form 4: RAPT Director Receives Annual Equity Grant

RAPT Therapeutics Director Mary Ann Gray was granted 4,956 restricted stock units as part of her annual compensation, vesting in one year.

Summary

• Mary Ann Gray, a Director of RAPT Therapeutics, Inc. (RAPT), acquired 4,956 shares of Common Stock.
• The transaction occurred on January 30, 2026.
• This acquisition represents an annual grant of restricted stock units (RSUs) under the company's Amended & Restated Non-Employee Director Compensation Policy.
• Each RSU grants a contingent right to receive one share of common stock upon vesting.
• The RSUs are scheduled to fully vest on the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine corporate governance and compensation practices that align director interests with shareholders, without indicating any new operational or financial developments.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of the shareholders, promoting long-term value creation.
• This is a standard component of non-employee director compensation, indicating adherence to established corporate governance practices.

Future Outlook

The granted restricted stock units are scheduled to fully vest on the first anniversary of the grant date, which is January 30, 2027, contingent on continued service.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units to non-employee directors is a common practice across the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain qualified board members while aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The use of restricted stock units for non-employee director compensation is a widely adopted practice, comparable to compensation structures seen at peer companies in the biotech sector such as Moderna (MRNA) or BioNTech (BNTX), which also utilize equity grants to incentivize directors.
• The one-year vesting schedule for annual RSU grants is typical for director compensation, ensuring continued engagement and alignment over a reasonable period.

Related Party Transactions

• The grant of 4,956 restricted stock units to Director Mary Ann Gray constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's long-term interests with shareholder value, potentially fostering more strategic decision-making.
• Employees: No direct impact on general employees is indicated by this director-specific compensation event.

Next Steps

• The restricted stock units are expected to fully vest on January 30, 2027, contingent upon the director's continued service.

Key Dates

Recommendation

This Form 4 reports a routine annual equity grant to a non-employee director, which is a standard compensation practice and does not provide new information to alter the fundamental investment thesis for RAPT Therapeutics. Investors should continue to monitor the company's operational and financial performance for material changes.

Keywords

RAPT Therapeutics, RAPT, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant